Advancing information highlight retatrutide, a dual stimulant for GLP-1 and GIPR, reveal promising possibility in managing obesity and connected metabolic ailments. Early clinical trials suggest notable fat reduction https://retatrutideresearchlab.co.uk/product/ozempic-025-mg/